Enigma of Intramuscular Triamcinolone Acetonide (Kenalog
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
accepted:
07
08
2023
medline:
25
8
2023
pubmed:
20
8
2023
entrez:
19
8
2023
Statut:
ppublish
Résumé
Triamcinolone acetonide is a glucocorticosteroid used in standard clinical practice for its anti-inflammatory properties. Although it can be given via different routes of administration, the intramuscular route is unique compared with other corticosteroids-its effects remain potent over a longer period of time. We summarize the existing literature on the pharmacokinetic and pharmacodynamic mechanisms of intramuscular triamcinolone acetonide (Kenalog
Identifiants
pubmed: 37598107
doi: 10.1007/s40262-023-01297-5
pii: 10.1007/s40262-023-01297-5
doi:
Substances chimiques
Triamcinolone Acetonide
F446C597KA
Esters
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1189-1199Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Ferguson DC, Dirikolu L, Hoenig M. Glucocorticoids, mineralocorticoids, and adrenolytic drugs. In: Riviere JE, Papich MG, Adams HR, editors. Veterinary pharmacology and therapeutics. 9th ed. Ames: Wiley-Blackwell; 2009. p. 783–4.
McLeod DT, Capewell SJ, Law J, MacLaren W, Seaton A. Intramuscular triamcinolone acetonide in chronic severe asthma. Thorax. 1985;40(11):840–5. https://doi.org/10.1136/thx.40.11.840 .
doi: 10.1136/thx.40.11.840
pubmed: 3906999
pmcid: 1020562
Frisbie DD, Kawcak CE, Trotter GW, et al. Effects of triamcinolone acetonide on an in vivo equine osteochondral fragment exercise model. Equine Vet J. 1997;29:349–59.
doi: 10.1111/j.2042-3306.1997.tb03138.x
pubmed: 9306060
Owen RA, Marsh JA, Hallett FR, et al. Intra-articular, corticosteroid- and exercise-induced arthropathy in a horse. J Am Vet Med Assoc. 1984;184:302–8.
pubmed: 6698863
Wolverton SE, Wu JJ. Comprehensive dermatologic drug therapy. Philadelphia: Elsevier; 2021.
Soma LR, Uboh CE, You Y, Guan F, Boston RC. Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. Am J Vet Res. 2011;72(9):1234–42. https://doi.org/10.2460/ajvr.72.9.1234 .
doi: 10.2460/ajvr.72.9.1234
pubmed: 21879982
Kusama M, Sakauchi N, Kumaoka S. Studies of plasma levels and urinary excretion after intramuscular injection of triamcinolone acetonide. Metabolism. 1971;20(6):590–6. https://doi.org/10.1016/0026-0495(71)90007-2 .
doi: 10.1016/0026-0495(71)90007-2
pubmed: 4325410
Derendorf H, Möllmann H, Grüner A, Haack D, Gyselby G. Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther. 1986;39(3):313–7. https://doi.org/10.1038/clpt.1986.45 .
doi: 10.1038/clpt.1986.45
pubmed: 3948470
Döppenschmitt SA, Scheidel B, Harrison F, Surmann JP. Simultaneous determination of triamcinolone acetonide and hydrocortisone in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996;682(1):79–88. https://doi.org/10.1016/0378-4347(96)00060-6 .
doi: 10.1016/0378-4347(96)00060-6
pubmed: 8832428
Derendorf H, Hochhaus G, Rohatagi S, et al. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol. 1995;35(3):302–5. https://doi.org/10.1002/j.1552-4604.1995.tb04064.x .
doi: 10.1002/j.1552-4604.1995.tb04064.x
pubmed: 7608322
Coll S, Monfort N, Alechaga É, Matabosch X, Pérez-Mañá C, Ventura R. Additional studies on triamcinolone acetonide use and misuse in sports: elimination profile after intranasal and high-dose intramuscular administrations. Steroids. 2019;151:108464. https://doi.org/10.1016/j.steroids.2019.108464 .
doi: 10.1016/j.steroids.2019.108464
pubmed: 31344406
Lamer TJ, Dickson RR, Gazelka HM, et al. Serum triamcinolone levels following cervical interlaminar epidural injection. Pain Res Manag. 2018;2018:1–5. https://doi.org/10.1155/2018/8474127 .
doi: 10.1155/2018/8474127
Matabosch X, Pozo OJ, Papaseit E, et al. Detection and characterization of triamcinolone acetonide metabolites in human urine by liquid chromatography/tandem mass spectrometry after intramuscular administration. Rapid Commun Mass Spectrom. 2014;28(16):1829–39. https://doi.org/10.1002/rcm.6965 .
doi: 10.1002/rcm.6965
pubmed: 25559453
Moore CD, Roberts JK, Orton CR, et al. Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013;41(2):379–89. https://doi.org/10.1124/dmd.112.046318 .
doi: 10.1124/dmd.112.046318
pubmed: 23143891
pmcid: 3558858
Firestein GS, Paine MM, Littman BH. Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA–DR) in rheumatoid arthritis and osteoarthritis synovium. Quantitative analysis and effect of intraarticular corticosteroids. Arthritis Rheum. 1991;34(9):1094–105. https://doi.org/10.1002/art.1780340905 .
doi: 10.1002/art.1780340905
pubmed: 1657009
Sun W, Ho S, Fang XR, O’Shea T, Liu H. Simultaneous determination of triamcinolone hexacetonide and triamcinolone acetonide in rabbit plasma using a highly sensitive and selective UPLC-MS/MS method. J Pharm Biomed Anal. 2018;153:267–73. https://doi.org/10.1016/j.jpba.2018.02.052 .
doi: 10.1016/j.jpba.2018.02.052
pubmed: 29550043
Frey H, Norman N. Duration of action of depot-corticosteroids. II. Triamcinolone acetonide and triamcinolone diacetate. Eur J Clin Pharmacol. 1971;3(4):229–31. https://doi.org/10.1007/BF00565011 .
doi: 10.1007/BF00565011
pubmed: 5151305
Seo J, Lee YI, Hwang S, Zheng Z, Kim DY. Intramuscular triamcinolone acetonide: an undervalued option for refractory alopecia areata. J Dermatol. 2016;44(2):173–9. https://doi.org/10.1111/1346-8138.13533 .
doi: 10.1111/1346-8138.13533
pubmed: 27448451
Wakelin S, Archer C, Maibach H (Eds.). Corticosteroids. In: Handbook of systemic drug treatment in dermatology (2nd ed.). Boca Raton: CRC Press; 2015. https://www.taylorfrancis.com/books/edit/10.1201/b18491/handbook-systemic-drug-treatment-dermatology-clivearcher-howard-maibach-sarah-wakelin.
Mayer M, Kaiser N, Milholland RJ, Rosen F. The binding of dexamethasone and triamcinolone acetonide to glucocorticoid receptors in rat skeletal muscle. J Biol Chem. 1974;249(16):5236–40. https://doi.org/10.1016/s0021-9258(19)42353-3 .
doi: 10.1016/s0021-9258(19)42353-3
pubmed: 4369267
Smith K, Shuster S. Characterization and quantification of epidermal and dermal glucocorticoid receptors in the rat. J Investig Dermatol. 1984;82(1):44–8. https://doi.org/10.1111/1523-1747.ep12259088 .
doi: 10.1111/1523-1747.ep12259088
pubmed: 6690629
Do YS, Feldman D. Heterogeneity of glucocorticoid binders: a high affinity triamcinolone acetonide binder in bovine serum. Endocrinology. 1980;107(5):1370–5. https://doi.org/10.1210/endo-107-5-1370 .
doi: 10.1210/endo-107-5-1370
pubmed: 6775927
Bae YJ, Kratzsch J. Corticosteroid-binding globulin: modulating mechanisms of bioavailability of cortisol and its clinical implications. Best Pract Res Clin Endocrinol Metabol. 2015;29(5):761–72. https://doi.org/10.1016/j.beem.2015.09.001 .
doi: 10.1016/j.beem.2015.09.001
Henley D, Lightman S, Carrell R. Cortisol and CBG: getting cortisol to the right place at the right time. Pharmacol Ther. 2016;166:128–35. https://doi.org/10.1016/j.pharmthera.2016.06.020 .
doi: 10.1016/j.pharmthera.2016.06.020
pubmed: 27411675
Samdani AJ. Dermatophyte growth and degradation of human stratum corneum in vitro (pathogenesis of dermatophytosis). J Ayub Med Coll Abbottabad. 2005;17(4):19–21.
pubmed: 16599028
Hu S, Lan C-CE. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci. 2017;18(10):2211. https://doi.org/10.3390/ijms18102211 .
doi: 10.3390/ijms18102211
pubmed: 29065479
pmcid: 5666891
Younes AK, Younes NK. Recovery of steroid induced adrenal insufficiency. Transl Pediatr. 2017;6(4):269–73. https://doi.org/10.21037/tp.2017.10.01 .
doi: 10.21037/tp.2017.10.01
pubmed: 29184808
pmcid: 5682381
Wikipedia. Triamcinolone. Published July 16, 2022. https://en.wikipedia.org/wiki/triamcinolone . Accessed 21 July 2022.
Wikipedia. Triamcinolone acetonide. Published July 16, 2022. https://en.wikipedia.org/wiki/triamcinolone_acetonide . Accessed 21 July 2022.
Wikipedia. Triamcinolone hexacetonide. Published April 23, 2022. https://en.wikipedia.org/wiki/triamcinolone_hexacetonide . Accessed 22 July 2022.
Matabosch X, Pozo OJ, Pérez-Mañá C, et al. Evaluation of the reporting level to detect triamcinolone acetonide misuse in sports. J Steroid Biochem Mol Biol. 2015;145:94–102. https://doi.org/10.1016/j.jsbmb.2014.09.018 .
doi: 10.1016/j.jsbmb.2014.09.018
pubmed: 25260353
Knych HK, Vidal MA, Casbeer HC, McKemie DS. Pharmacokinetics of triamcinolone acetonide following intramuscular and intra-articular administration to exercised thoroughbred horses. Equine Vet J. 2013;45(6):715–20. https://doi.org/10.1111/evj.12059 .
doi: 10.1111/evj.12059
pubmed: 23574452
Reddy S, Ananthakrishnan S, Garg A. A prospective observational study evaluating hypothalamic–pituitary–adrenal axis alteration and efficacy of intramuscular triamcinolone acetonide for steroid-responsive dermatologic disease. J Am Acad Dermatol. 2013;69(2):226–31. https://doi.org/10.1016/j.jaad.2013.02.005 .
doi: 10.1016/j.jaad.2013.02.005
pubmed: 23545370
Abraham G, Demiraj F, Ungemach FR. Comparison of the hypothalamic–pituitary–adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. J Endocrinol. 2006;191(2):491–6. https://doi.org/10.1677/joe.1.06991 .
doi: 10.1677/joe.1.06991
pubmed: 17088419
Robins DN. Intramuscular triamcinolone: a safe, effective and underutilized dermatologic therapy. J Drugs Dermatol. 2009;8(6):580–5.
pubmed: 19537385
French K, Pollitt CC, Pass MA. Pharmacokinetics and metabolic effects of triamcinolone acetonide and their possible relationships to glucocorticoid-induced laminitis in horses. J Vet Pharmacol Ther. 2000;23(5):287–92. https://doi.org/10.1046/j.1365-2885.2000.00288.x .
doi: 10.1046/j.1365-2885.2000.00288.x
pubmed: 11107002
Yao Q, Guo Y, Xue J, et al. Development and validation of a LC–MS/MS method for simultaneous determination of six glucocorticoids and its application to a pharmacokinetic study in nude mice. J Pharm Biomed Anal. 2020;179:112980. https://doi.org/10.1016/j.jpba.2019.112980 .
doi: 10.1016/j.jpba.2019.112980
pubmed: 31744668
Doty AC, Weinstein DG, Hirota K, et al. Mechanisms of in vivo release of triamcinolone acetonide from PLGA microspheres. J Control Release. 2017;256:19–25. https://doi.org/10.1016/j.jconrel.2017.03.031 .
doi: 10.1016/j.jconrel.2017.03.031
pubmed: 28342981
Pershing LK, et al. Skin blanching response to topical corticosteroids reflects ADD allelic haplotype associated with fast alcohol metabolizing isoforms. J Investig Dermatol. 2004;122:A46.
Pershing LK. Assessment of topical corticosteroid-induced skin blanching response using the visual McKenzie–Stoughton and colorimetric methods. Drug Inf J. 1995;29(3):923–34. https://doi.org/10.1177/009286159502900314 .
doi: 10.1177/009286159502900314
Raney SG, Ghosh P, Ramezanli T, Lehman PA, Franz TJ. Cutaneous pharmacokinetic approaches to compare bioavailability and/or bioequivalence for topical drug products. Dermatol Clin. 2022;40(3):319–32. https://doi.org/10.1016/j.det.2022.02.007 .
doi: 10.1016/j.det.2022.02.007
pubmed: 35750415
Mikhail GR. Long-term intramuscular administration of triamcinolone acetonide. Arch Dermatol. 1977;113(1):111–211. https://doi.org/10.1001/archderm.113.1.111 .
doi: 10.1001/archderm.113.1.111
pubmed: 831617